Study to Compare the Efficacy and Safety of Administration of the Fix Dose Combination of Linagliptin Plus Metformin in Drug naïve Type 2 Patients

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 876 participants.

Also called NCT01708902

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 876 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01708902
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
China, Malaysia, Philippines, Vietnam (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01708902. Randomized; double masking; primary purpose treatment. Start 2012-10 (registry gives no type); primary completion 2014-04 (actual). Results posted on 2015-04-24.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Compare the Efficacy and Safety of Administration of the Fix Dose Combination of Linagliptin Plus Metformin in Drug naïve Type 2 Patients
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
linagliptin2.5mg/metformin1000mg
Intervention (Drug)
linagliptin2.5mg/metformin1000mg
Intervention (Drug)
linagliptin 5mg
Intervention (Drug)
Metformin 500mg
Intervention (Drug)
linagliptin2.5mg/metformin500mg
Intervention (Drug)
linagliptin2.5mg/metformin500mg
Intervention (Drug)
linagliptin 5mg
Intervention (Drug)
Metformin 1000mg
Lead sponsor
Boehringer Ingelheim (class: industry)
Collaborator
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct01708902
Content hash
784c9d700bac5c697e664ef228dd31f19e4f3883ff452843eab92bbe4925457d